YC - 1, solide

Non disponible en dehors du Royaume-Uni et de l'Irlande

Application

YC-1 has been used as a hypoxia-inducible factor 1α (HIF-1α) inhibitor:to reduce hypoxia induced Jagged1 expression in cardiomyocytes (CMs)to study its effect on progenitor expansion and CD34+ and side population (SP) cell phenotype and on the proliferation rate of cells with an ability to form long term colony forming unitsto study its effect on regulating sphingosine 1-phosphate (S1P) bound to albumin induced plasminogen activator inhibitor 1 (PAI-1) expression by activating Rho/ Rho-associated protein kinase (ROCK) pathway.

Biochem/physiol Actions

YC-1 activates soluble guanylyl cyclase and prevents platelet aggregation and vascular contraction. It has a potential to treat circulation disorders. YC-1 also has an ability to inhibit hypoxia-inducible factor 1α (HIF-1α) activity in vitro. It acts as a potential antiangiogenic anticancer agent.

NO (nitric oxide)-independent activator of soluble guanylyl cyclase.

Features and Benefits

This compound is a featured product for Cyclic Nucleotide research. Click here to discover more featured Cyclic Nucleotide products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

Packaging

5 mg in glass bottle

25 mg in glass insert